Delivery Order SPE2DB22D2005-SPE2DB25FJNV8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $2,050.33 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on August 26, 2025, for Quillivant XR 25 mg/5 mL suspension (60 mL), with a ceiling value of $3,154.08. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 27, 2025. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract by the Defense Logistics Agency (DLA) on June 18, 2025, valued at $1,597.18 for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml). The contract is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 20, 2025. Performance will occur at the vendor's corporate office location in Conshohocken, PA. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with a ceiling value of $1,202.39. This firm fixed price delivery order, which will be completed by October 30, 2025, represents a non-competitive, open-market award supporting federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,253.59 and an ultimate completion date of September 19, 2025. The award represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,164.94 to supply Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with an ultimate completion date of November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on November 3, 2025, with no set-aside designation. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJNV8Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on June 20, 2025, valued at $1,901.20 for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. The product will be delivered to the company's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of June 23, 2025. Quillivant XR is a long-acting ADHD medication used in military and veteran healthcare systems, consistent with AmerisourceBergen's established role as a major pharmaceutical distributor for federal medical procurement. As a prime vendor under the DLA Troop Support Medical contract, AmerisourceBergen supplies a broad spectrum of pharmaceutical products and medical supplies to support Defense Health Agency operations and other government healthcare systems. This delivery order exemplifies the company's capability to fulfill small-value, time-sensitive pharmaceutical requirements through the existing IDC framework, enabling rapid procurement of critical medications for military medical facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 6/20/25 |